RedHill Biopharma (RDHL) Accounts Payables (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Accounts Payables data on file, last reported at $731000.0 in Q4 2025.

• Accounts Payables for Q4 2025 came in at $731000.0, down 37.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $731000.0 (down 37.41% YoY), and the FY2025 annual result was $731000.0, down 37.41% from the prior year.
• Accounts Payables declined to $731000.0 in Q4 2025 per RDHL's latest filing, from $835000.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $15.2 million in Q3 2021 and troughed at $731000.0 in Q4 2025.
• A 5-year average of $5.4 million and a median of $4.4 million in 2023 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2021 and 2022: Accounts Payables surged 150.68% in 2021, then tumbled 68.62% in 2022.
• A 5-year view of Accounts Payables shows it stood at $11.7 million in 2021, then tumbled by 63.73% to $4.2 million in 2022, then slipped by 22.51% to $3.3 million in 2023, then sank by 64.37% to $1.2 million in 2024, then plunged by 37.41% to $731000.0 in 2025.
• Business Quant data shows RDHL's Accounts Payables at $731000.0 in Q4 2025, $835000.0 in Q2 2025, and $1.2 million in Q4 2024.